298 patents currently held

95 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

64 more records may belong here and await a decision; they are not counted.

The next term ends in Dec 2026. from the record

Of the 95 now held by other companies, 20 were conveyed to MedImmune Limited in the filing they arrived in, and 75 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Dec 2026

Next term end

179

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045

notable patents fee due within 90 days all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase 1 Inhibitors US 11,655,222

Cited by 19 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.

Ends Jan 2035 · Low confidence Also notable

2-(2,4,5-Substituted-ANILINO) Pyrimidine Compounds US 8,946,235

Cited by 45 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.

Ends Aug 2032 · High confidence Also notable

Chemical Compounds US 9,018,381

Cited by 51 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.

Ends Dec 2032 · High confidence

Formerly held, still cited

Notable

Targeted Binding Agents Against B7-H1 US 8,779,108

The most cited patent in this portfolio, cited by 166 later US patents, top 5% of utility patents granted in 2014 in our data. Protection runs to 2030.

now held by MedImmune Limited

Ends Nov 2030 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

9 fees due Dec 6 to 30, 2026 · next Dec 6
3 fees due Jan 2 to 14, 2027 · next Jan 2
4 fees due Feb 8 to 28, 2027 · next Feb 8
7 fees due Mar 3 to 24, 2027 · next Mar 3
7 fees due Apr 3 to 29, 2027 · next Apr 3
2 fees due May 14 to 28, 2027 · next May 14
3 fees due Jun 17 to 24, 2027 · next Jun 17
5 fees due Jul 2 to 30, 2027 · next Jul 2
5 fees due Aug 2 to 27, 2027 · next Aug 2
6 fees due Sep 3 to 26, 2027 · next Sep 3
5 fees due Oct 9 to 30, 2027 · next Oct 9
1 fee due Nov 7, 2027
The maintenance fee for 1-[2-(AMINOMETHYL)BENZYL]-2-Thioxo-1,2,3,5-Tetrahydro-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE (US 11,975,004) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nov 11Assignment recorded on 1 record: AstraZeneca UK Limited to AstraZeneca AB Recorded Nov 11, 2026, executed Feb 7, 2024. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76710, frame 908.
Nov 11Assignment recorded on 1 record: Panknin, Olaf and 2 others to AstraZeneca AB Recorded Nov 11, 2026, executed Feb 16, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76711, frame 17.
13 of the patents on this record were granted since Aug 16, 2026
14 terms have ended since Aug 16, 2026

What they patent

The 5 largest of its 179 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Certain (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase 1 Inhibitors	16 in force	to Mar 2035
Systems and Methods for Dispensing a Statin Medication Over the Counter	9 in force	to Jun 2038
A Substituted Pyrrolo[2,3-d]pyrimidine as a Protein Kinase B Inhibitor	7 in force	to Mar 2030
1-[2-(AMINOMETHYL)BENZYL]-2-Thioxo-1,2,3,5-Tetrahydro-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE	5 in force	to Dec 2036
Pyrazole Derivatives Useful as 5-Lipoxygenase Activating Protein (FLAP) Inhibitors	5 in force	to May 2036

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 7,709,511	Novel Benzothiazolone Derivatives In force Term ends Dec 11, 2026 · High confidence	In force	Term ends Dec 11, 2026	High confidence
US 7,425,556	Compounds and Uses Thereof In force Term ends Dec 18, 2026 · High confidence	In force	Term ends Dec 18, 2026	High confidence
US 7,465,795	Compounds and Uses Thereof In force Ends no later than Dec 18, 2026 · Medium confidence	In force	Ends no later than Dec 18, 2026	Medium confidence
US 8,859,568	Pyrrolo[3,2-d]pyrimidin-4-one Derivatives and Their Use in Therapy In force Term ends Mar 4, 2027 · Medium confidence	In force	Term ends Mar 4, 2027	Medium confidence
US 8,387,615	Inhaler Cap Strap In force Term ends Mar 26, 2027 · High confidence	In force	Term ends Mar 26, 2027	High confidence
US 8,051,851	Inhaler for the Administration of Powdered Pharmaceuticals, and a Powder Cartridge System for Use with This Inhaler In force Term ends Apr 22, 2027 · High confidence	In force	Term ends Apr 22, 2027	High confidence
US 8,501,698	Crystal Structures of SGLT2 Inhibitors and Processes for Preparing Same In force Term ends Jun 20, 2027 · High confidence	In force	Term ends Jun 20, 2027	High confidence
US 7,829,707	Pyrrolo [3,2-d]pyrimidin-4-one Derivatives and Their Use in Therapy In force Term ends Jun 23, 2027 · High confidence	In force	Term ends Jun 23, 2027	High confidence
US D685,460	Tablet In force Ends no later than Jul 2, 2027 · Medium confidence	In force	Ends no later than Jul 2, 2027	Medium confidence
US 8,063,073	2-Pyridone Derivatives as Neutrophil Elastase Inhibitors and Their Use In force Term ends Jul 26, 2027 · High confidence	In force	Term ends Jul 26, 2027	High confidence

10 of 298 patents shown.

Pro members see all 298.

Pro members: see all 298 patents

Also on record, not counted in the 298: 95 patents in force now held by others · 1,016 patents ended · 279 applications pending · 1,516 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

AstraZeneca AB